G2/M blockade by paclitaxel induces caveolin-1 expression in A549 lung cancer cells:: caveolin-1 as a marker of cytotoxicity

被引:15
作者
Roussel, É [1 ]
Bélanger, MM [1 ]
Couet, J [1 ]
机构
[1] Univ Laval, Hop Laval, Ctr Rech, Unite Rech Pneumol,Inst Univ Cardiol & Pneumol, St Foy, PQ G1V 4G5, Canada
关键词
caveolae; caveolin; lung cancer; paclitaxel;
D O I
10.1097/00001813-200411000-00005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Caveolins are highly expressed in terminally differentiated cells, but this expression is down-regulated in various cancer cell lines. Exposure to low doses of paclitaxel (taxol) is sufficient to up-regulate caveolin-1, suggesting that a mild cytotoxic stress induces a response implying caveolin and caveolae. Here we show that this upregulation is sustained even after the cessation of paclitaxel treatment. After exposure to a cytostatic dose of paclitaxel (50 nM), A549 lung cancer cells are blocked in the G(2)/M cell cycle phase. After removal of paclitaxel, cell death occurs, accompanied with an increase in caveolin expression, suggesting an effect of caveolin in this process. Three days post-paclitaxel treatment, surviving A549 cells were passaged and only a half of them adhered to the culture dish. Adhering cells (still mainly in the G(2)/M cell cycle phase) were still unable to grow and progressively entered in an apoptotic state. This study suggests that effects of a low dose of paclitaxel were still present even 1 week after drug removal and that caveolin-1 is a good marker of cytotoxicity. (C) 2004 Lippincott Williams Wilkins.
引用
收藏
页码:961 / 967
页数:7
相关论文
共 32 条
[1]   Up-regulation of caveolin expression by cytotoxic agents in drug-sensitive cancer cells [J].
Bélanger, MM ;
Roussel, É ;
Couet, J .
ANTI-CANCER DRUGS, 2003, 14 (04) :281-287
[2]  
Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO
[3]  
2-5
[4]   Paclitaxel-induced FasL-independent apoptosis and slow (non-apoptotic) cell death [J].
Blagosklonny, MV ;
Robey, R ;
Sheikh, MS ;
Fojo, T .
CANCER BIOLOGY & THERAPY, 2002, 1 (02) :113-117
[5]   Cell biology of caveolae and caveolin [J].
Couet, J ;
Belanger, MM ;
Roussel, E ;
Drolet, MC .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 49 (03) :223-235
[6]   Identification of peptide and protein ligands for the caveolin-scaffolding domain - Implications for the interaction of caveolin with caveolae-associated proteins [J].
Couet, J ;
Li, SW ;
Okamoto, T ;
Ikezu, T ;
Lisanti, MP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (10) :6525-6533
[7]   Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo - A role for the caveolin-scaffolding domain [J].
Engelman, JA ;
Chu, C ;
Lin, A ;
Jo, H ;
Ikezu, T ;
Okamoto, T ;
Kohtz, DS ;
Lisanti, MP .
FEBS LETTERS, 1998, 428 (03) :205-211
[8]   Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth [J].
Engelman, JA ;
Wykoff, CC ;
Yasuhara, S ;
Song, KS ;
Okamoto, T ;
Lisanti, MP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (26) :16374-16381
[9]   p42/44 MAP kinase-dependent and -independent signaling pathways regulate caveolin-1 gene expression - Activation of Ras-MAP kinase and protein kinase A signaling cascades transcriptionally down-regulates caveolin-1 promoter activity [J].
Engelman, JA ;
Zhang, XL ;
Razani, B ;
Pestell, RG ;
Lisanti, MP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (45) :32333-32341
[10]   Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade [J].
Galbiati, F ;
Volonté, D ;
Engelman, JA ;
Watanabe, G ;
Burk, R ;
Pestell, RG ;
Lisanti, MP .
EMBO JOURNAL, 1998, 17 (22) :6633-6648